John Sperzel discusses how T2 Biosystems technology is an improvement over the current standard of care for detecting bloodstream infections (BSI) as well as T2’s response to the COVID-19 pandemic. He also outlines T2 Biosystems’ first-quarter earnings for 2021 and the future pipeline of products. Sperzel also shares information about his book, Courage: Powerful Lessons in Leadership, Strength, and the Will to Succeed, as it relates to his personal history as a heart transplant recipient as a sepsis survivor.
John Sperzel shares more details about his history as a transplant recipient and sepsis survivor, and how his journey led him to join T2 Biosystems as President and CEO. In addition to his story, he also discusses the limitations of the current standard of care for sepsis in US hospitals.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2024 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States
